Bausch Health Companies (TSE:BHC) Trading Down 7.9%

Shares of Bausch Health Companies Inc. (TSE:BHC - Get Free Report) fell 7.9% on Thursday . The stock traded as low as C$11.05 and last traded at C$11.08. 151,303 shares changed hands during mid-day trading, a decline of 57% from the average session volume of 350,637 shares. The stock had previously closed at C$12.03.

Analyst Upgrades and Downgrades

Separately, Royal Bank of Canada increased their target price on Bausch Health Companies from C$8.00 to C$9.00 and gave the company a "sector perform" rating in a research report on Friday, February 23rd.

Bausch Health Companies Price Performance

The company has a debt-to-equity ratio of 7,583.76, a current ratio of 1.30 and a quick ratio of 0.58. The firm has a fifty day moving average of C$12.67 and a two-hundred day moving average of C$11.13. The stock has a market capitalization of C$4.04 billion, a P/E ratio of -5.02, a P/E/G ratio of 0.21 and a beta of 0.83.

Bausch Health Companies (TSE:BHC - Get Free Report) last announced its earnings results on Thursday, February 22nd. The company reported C$1.55 EPS for the quarter, topping analysts' consensus estimates of C$1.36 by C$0.19. The business had revenue of C$3.28 billion during the quarter, compared to the consensus estimate of C$3.05 billion. Bausch Health Companies had a negative net margin of 6.76% and a negative return on equity of 686.52%. On average, analysts predict that Bausch Health Companies Inc. will post 4.9511278 EPS for the current year.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.